<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04346381</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1210-II-215</org_study_id>
    <nct_id>NCT04346381</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor</brief_title>
  <official_title>An Open-label, Multi-centerï¼ŒPhase II Study of Camrelizumab Combined With Famitinib in the Treatment of Advanced Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center study to evaluate the anti-tumor activity and safety of
      camrelizumab combined famitinib in subjects with selected advanced solid tumor.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Response Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Progression-free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>Up to 18months</time_frame>
    <description>Duration of Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>Up to 18months</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTR</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Time to Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>overall survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0 (SAEs) as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of dose suspension, dose reduction or dose discontinuation caused by treatment-related toxicities.</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Proportion of dose suspension, dose reduction or dose discontinuation caused by treatment-related toxicities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of anti-camrelizumab antibody (ADA) and neutralizing antibody (Nab) formed during the study from baseline</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Proportion of anti-camrelizumab antibody (ADA) and neutralizing antibody (Nab) formed during the study from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of camrelizumab</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Serum concentration of camrelizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of famitinib</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Plasma concentration of famitinib</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">205</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>camrelizumab combined with famitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive camrelizumab on Day 1of each cycle and famitinib qd up to 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Intravenous (IV) camrelizumab on Day 1 of each cycle</description>
    <arm_group_label>camrelizumab combined with famitinib</arm_group_label>
    <other_name>SHR-1210</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famitinib</intervention_name>
    <description>famitinib po qd</description>
    <arm_group_label>camrelizumab combined with famitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically- or cytologically-confirmed diagnosis of advanced solid tumor.

          2. Willing to provide tumor tissue for PD-L1 biomarker analysis.

          3. At least one measurable lesion according to RECIST 1.1.

          4. ECOG performance status of 0 to 1.

          5. Life expectancy of more than 12 weeks.

          6. Signing the informed consent forms.

          7. Adequate bone marrow, liver and renal function.

        Exclusion Criteria:

          1. Subjects with untreated central nervous system (CNS) metastases.

          2. Subjects with an active, known or suspected autoimmune disease.

          3. Subjects with clinically significant cardiovascular and cerebrovascular diseases.

          4. Subjects with high blood pressure who cannot be controlled well with antihypertensive
             drugs.

          5. Subjects with previous digestive tract bleeding history within 3 months or evident
             gastrointestinal bleeding tendency.

          6. Subjects with arterial / venous thrombosis events occurred within 6 months of the
             first dose.

          7. Subjects who have previously received anti-PD-1 / PD-L1 monoclonal antibody,
             anti-CTLA-4 monoclonal antibody, and VEGFR small molecule inhibitor therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Quanren Wang, PhD</last_name>
    <phone>18036618570</phone>
    <email>wangquanren@hrglobe.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia Fan, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

